Program
SAR444336
A development code.
In Sanofi's pipeline, Non-beta IL2 Synthorin
. Its studies are mostly in Colitis, Microscopic, led by Sanofi.
Furthest: phase 2, since Sep 3, 20252 company-led studies, 1 open or runningNext primary completion: Apr 8, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 21 open or running | phase 2since Sep 3, 2025 | May 17, 2023 | Apr 8, 2027phase 2 · NCT07156175 |
- Named in Sanofi’s own pipeline as
SAR444336
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2023First study: phase 1 study in Healthy VolunteerFirst studyNCT05876767 · 76 enrolled · Netherlands
- Sep 3, 2025Phase 2 study in Colitis, MicroscopicNCT07156175 · 60 enrolled · Belgium, Denmark, France and more
Ahead
- Apr 8, 2027Primary completion: phase 2 study in Colitis, MicroscopicNCT07156175
TargetBeta
“Non-beta IL2 Synthorin”the company's pipeline, read by Claude · source
Other programs on IL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| darleukinrule | Philogen | phase 3 | 9 |
| daromunrule | Philogen | phase 3 | 6 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
| Anti-PD-1/IL-2 Fusion Protein TEV-56278 | Teva Pharmaceutical Industries | phase 1 | 2 |
| IL-2 Mutein/Fc Fusion Protein HM16390rule | Hanmi Pharmaceutical | phase 1 | 1 |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07156175Colitis, Microscopic · Belgium, Denmark, France and more | 2 | Active, not recruiting | Apr 8, 2027 | 60 |
| NCT05876767Healthy Volunteer · Netherlands | 1 | Completed | Dec 12, 2023 | 76 |
How it is read
Names in the registry
- “SAR444336”, 2 entries
Codes read as this program: SAR444336.
Conditions, from the studies’ own filings
- Colitis, Microscopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.